Boehringer Ingelheim
Erin Mangan, PhD, is an accomplished pharmaceutical and biotechnology executive with extensive experience in leadership roles. Currently serving as Executive Director and Therapeutic Area Head for Immunology and Biosimilars at Boehringer Ingelheim since April 2020, Erin specializes in Rare Diseases, Immunology, Dermatology, Rheumatology, GI, and Biosimilars, demonstrating a strong ability to build high-functioning teams and devise comprehensive medical affairs strategies throughout product life cycles. Previously, Erin held significant roles at Regeneron Pharmaceuticals and Pfizer, including senior positions that involved strategic planning, medical operations, and product launch initiatives for brands such as Toviaz and Duavee. Educational qualifications include a Ph.D. in Biochemistry from UCLA, combined with extensive post-doctoral training in Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, and a bachelor's degree in Chemistry from Valparaiso University.
This person is not in any teams
This person is not in any offices
Boehringer Ingelheim
116 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.